Home/Pipeline/S-pindolol benzoate (ACM-001.1)

S-pindolol benzoate (ACM-001.1)

Cancer Cachexia

Phase 2Active

Key Facts

Indication

Cancer Cachexia

Phase

Phase 2

Status

Active

Company

Actimed Therapeutics

About Actimed Therapeutics

Actimed Therapeutics is a clinical-stage biotech pioneering treatments for cachexia and muscle wasting, a high-unmet-need area with no approved therapies. The company has a focused pipeline led by two clinical-stage assets, S-pindolol benzoate (ACM-001.1) and S-oxprenolol (ACM-002), repurposed enantiomers of existing beta-blockers. Recent strategic moves include a licensing agreement with Mankind Pharma and active data presentations at key medical conferences, positioning the company for potential partnerships and clinical advancement in a significant market opportunity.

View full company profile

Therapeutic Areas

Cachexia Muscle Wasting Disorders Oncology Supportive Care Metabolic Disorders

Other Cancer Cachexia Drugs

Drug	Company	Phase	Status
NGM120	NGM Biopharmaceuticals	Phase 2	Active
Mifomelatide (TCMCB07)	Endevica Bio	Phase 2	Active
Rilogrotug (AV-380)	AVEO Oncology	Phase 1/2	Active
Espindolol (MT-102)	Numedicus	Phase 2/Spin-out	Active